
Julian Harrison is a Director and BTIG Biotechnology Analyst. Prior to BTIG, he was an Equity Research Associate at H.C. Wainwright & Co., covering small- to mid-cap biotechnology and specialty pharmaceutical companies. Previously, Mr. Harrison was a Clinical and Translational Research Assistant at Hospital for Special Surgery. He earned a BS in biology from Cornell University and an MS in health economics from Weill Cornell Medical College.
BackCoverage Area
Company | Ticker |
---|---|
Aclaris Therapeutics | ACRS |
MoonLake Immunotherapeutics | MLTX |
CymaBay Therapeutics | CBAY |
United Therapeutics Corporation | UTHR |
Matinas BioPharma Holdings, Inc. | MTNB |
Protagonist Therapeutics, Inc. | PTGX |
Biora Therapeutics, Inc. | BIOR |
Rani Therapeutics Holdings, Inc. | RANI |
Aura Biosciences, Inc. | AURA |
Aerovate Therapeutics | AVTE |
Morphic Therapeutic | MORF |
Liquidia Corporation | LQDA |
Keros Therapeutics | KROS |
Outlook Therapeutics | OTLK |
Viridian Therapeutics | VRDN |